Abstract
Background: Abdominal aortic aneurysms (AAA) are life-threatening because of the potential for rupture, resulting in death. The current standard treatment for AAA is surgery, comprising laparotomic graft replacement and endovascular repair. However, because surgery carries the risk of major complications and re-intervention, drug therapies are desirable because they may reduce the occurrence of enlargement and rupture.
Objective: Recent research shows that the progression of AAA is related to inflammatory reactions, especially those in the NF-κB pathway. Omega-3 polyunsaturated fatty acids (PUFA) show antiinflammatory effects. Some derivatives of omega-3 PUFA are known as specialized pro-resolving lipid mediators (SPM) such as resolvins. They play an important role in resolving inflammation.
Conclusion: Omega-3 PUFA and SPM may show promised effects for drug treatment of AAA.
Keywords: Abdominal aortic aneurysm (AAA), drug therapy, inflammation, omega-3 polyunsaturated fatty acid (PUFA), resolvin, intraluminal thrombus.
Current Drug Targets
Title:Drug Therapy for Abdominal Aortic Aneurysms Utilizing Omega-3 Unsaturated Fatty Acids and Their Derivatives
Volume: 19 Issue: 11
Author(s): Daisuke Akagi*, Katsuyuki Hoshina, Toshiaki Watanabe and Micheal S. Conte
Affiliation:
- Division of Vascular and Endovascular Surgery, Department of Surgery, Cardiovascular Research Institute, University of California, San Francisco CA 94117,United States
Keywords: Abdominal aortic aneurysm (AAA), drug therapy, inflammation, omega-3 polyunsaturated fatty acid (PUFA), resolvin, intraluminal thrombus.
Abstract: Background: Abdominal aortic aneurysms (AAA) are life-threatening because of the potential for rupture, resulting in death. The current standard treatment for AAA is surgery, comprising laparotomic graft replacement and endovascular repair. However, because surgery carries the risk of major complications and re-intervention, drug therapies are desirable because they may reduce the occurrence of enlargement and rupture.
Objective: Recent research shows that the progression of AAA is related to inflammatory reactions, especially those in the NF-κB pathway. Omega-3 polyunsaturated fatty acids (PUFA) show antiinflammatory effects. Some derivatives of omega-3 PUFA are known as specialized pro-resolving lipid mediators (SPM) such as resolvins. They play an important role in resolving inflammation.
Conclusion: Omega-3 PUFA and SPM may show promised effects for drug treatment of AAA.
Export Options
About this article
Cite this article as:
Akagi Daisuke *, Hoshina Katsuyuki , Watanabe Toshiaki and Conte S. Micheal, Drug Therapy for Abdominal Aortic Aneurysms Utilizing Omega-3 Unsaturated Fatty Acids and Their Derivatives, Current Drug Targets 2018; 19 (11) . https://dx.doi.org/10.2174/1389450118666171013101815
DOI https://dx.doi.org/10.2174/1389450118666171013101815 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anti-Inflammatory Therapeutic Approaches to Reduce Acute Atherosclerotic Complications
Current Pharmaceutical Biotechnology Editorial [(Hot Topic Novel Drug Therapies in the Treatment of SAH) Guest Editors: Surya Karri and Christopher S. Ogilvy]
Current Drug Safety Revealing the Promoting Effect of Betaine on Vitamin B<sub>12</sub> Biosynthetic Pathway of <i>Pseudomonas denitrificans</i> by Using a Proteomics Analysis
Current Pharmaceutical Biotechnology Perspectives of Gene Therapies in Autosomal Dominant Polycystic Kidney Disease
Current Gene Therapy Entropy Model for Multiplex Drug-Target Interaction Endpoints of Drug Immunotoxicity
Current Topics in Medicinal Chemistry Aging and Remodeling During Healing of the Wounded Heart: Current Therapies and Novel Drug Targets
Current Drug Targets Coronary Stent Fracture: A Recently Appreciated Phenomenon with Clinical Relevance
Current Cardiology Reviews Neurotoxicity: The Broad Framework of Electron Transfer, Oxidative Stress and Protection by Antioxidants
Current Medicinal Chemistry - Central Nervous System Agents Exploring Optic Nerve Axon Regeneration
Current Neuropharmacology RAAS Inhibition and Cardiorenal Syndrome
Current Hypertension Reviews Regulation of Myocardial Extracellular Matrix Dynamic Changes in Myocardial Infarction and Postinfarct Remodeling
Current Cardiology Reviews Role of Transcranial Doppler Ultrasonography in Cerebrovascular Disease
Recent Patents on CNS Drug Discovery (Discontinued) Editorial (Thematic Issue: Therapeutic Applications of Advanced Drug Delivery Systems)
Current Pharmaceutical Design The Role of Oxidative Stress in Cerebral Aneurysm Formation and Rupture
Current Neurovascular Research Adverse Reactions and Pathogen Safety of Intravenous Immunoglobulin
Current Drug Safety Lipids and Non-Cardiac Vascular Disease: A Lecture Overview
Current Vascular Pharmacology New Designer Drugs (Synthetic Cannabinoids and Synthetic Cathinones): Review of Literature
Current Pharmaceutical Design A Fresh Prospect of Extracellular Matrix Hydrolytic Enzymes and Their Substrates
Current Pharmaceutical Design Signaling Through Rho GTPase Pathway as Viable Drug Target
Current Medicinal Chemistry Diabetic Papillopathy: Current and New Treatment Options
Current Diabetes Reviews